Werewolf Therapeutics (HOWL) Competitors

Werewolf Therapeutics (NASDAQ:HOWL) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Does the MarketBeat Community favor HOWL or ACIU?

AC Immune received 226 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. However, 70.83% of users gave Werewolf Therapeutics an outperform vote while only 62.65% of users gave AC Immune an outperform vote.

Company	Underperform	Outperform
Werewolf Therapeutics	Outperform Votes 34 70.83%	Underperform Votes 14 29.17%
AC Immune	Outperform Votes 260 62.65%	Underperform Votes 155 37.35%

Does the media refer more to HOWL or ACIU?

In the previous week, AC Immune had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for AC Immune and 1 mentions for Werewolf Therapeutics. AC Immune's average media sentiment score of 1.54 beat Werewolf Therapeutics' score of 0.66 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AC Immune	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do insiders and institutionals believe in HOWL or ACIU?

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 21.1% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, HOWL or ACIU?

Werewolf Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Is HOWL or ACIU more profitable?

AC Immune has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. AC Immune's return on equity of -28.26% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	-578.80%	-58.83%	-38.45%
AC Immune	N/A	-28.26%	-18.98%

Which has stronger earnings & valuation, HOWL or ACIU?

Werewolf Therapeutics has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.89M	21.47	-$37.37M	-$1.66	-0.54
AC Immune	$27.31M	6.07	-$60.41M	-$0.58	-2.84

Do analysts recommend HOWL or ACIU?

Werewolf Therapeutics currently has a consensus price target of $9.00, indicating a potential upside of 896.68%. AC Immune has a consensus price target of $12.00, indicating a potential upside of 627.27%. Given Werewolf Therapeutics' higher possible upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
AC Immune	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

AC Immune beats Werewolf Therapeutics on 9 of the 17 factors compared between the two stocks.